Patients With Atrial Fibrillation Receiving Oral Anticoagulants
Conditions
Brief summary
Atrial fibrillation (AF) is type of arrhythmia characterized by an irregular and often rapid heartbeats, it has strong associations with other cardiovascular diseases, such as heart failure, coronary artery disease (CAD), valvular heart disease, diabetes mellitus, thyrotoxicosis and hypertension. Atrial fibrillation is the most frequent cardiac arrhythmia. It has been estimated that 6-12 million people worldwide will suffer this condition in the US by 2050 and 17.9 million people in Europe by 2060. Atrial fibrillation is a major risk factor for ischemic stroke and provokes important economic burden along with significant morbidity and mortality . (AF) is arrhythmia with the potential to cause thromboembolism. Studies suggest that AF increases the risk of stroke five-folds. Stroke prevention is central to the management of patients with atrial fibrillation (AF), and effective stroke prevention requires oral anticoagulation (OAC). Either a vitamin K antagonist (VKA; e.g. warfarin) or a non-VKA oral anticoagulant (NOAC) . It's essential reach the balance between prevention of thromboembolic as well as bleeding events during the anticoagulant use.
Interventions
DRUGWarfarin
Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) & (ORBIT) SCORES will be calculated and compared for all cases .
Sponsors
Sohag University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* All patients with atrial fibrillation : 1. Aged 18 years old or older . 2. Underwent cardiac valve replacement 3. Who have valvular heart disease receiving anticoagulants . 4. Who have non valvular AF in whom CHA2DS 2VASc score 2 or more. 5. Receiving either vitamin K antagonist e.g warfarin or NOAC .
Exclusion criteria
1. Patients age less than 18 years old 2. Patients receiving anticoagulants without atrial fibrillations 3. Pregnant patients with AF 4. Patients with AF on Non oral anticoagulants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence of bleeding events using both (HAS-BLED) & (ORBIT) SCORES | 6 months | Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) & (ORBIT) SCORES will be calculated and compared for all cases . |
Contacts
Primary ContactYasmeen M Al-anwer, Resident
Backup Contactlotfy H Abo Dahab, Professor
Outcome results
None listed